Ethyl pyruvate modulates delayed paralysis following thoracic aortic ischemia reperfusion in mice

Bao Ngoc Nguyen, Hassan Albadawi, Rahmi Oklu, Robert S. Crawford, Mitchell P. Fink, Richard P. Cambria, Michael T. Watkins

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective Delayed paralysis is an unpredictable problem for patients undergoing complex repair of the thoracic/thoracoabdominal aorta. These experiments were designed to determine whether ethyl pyruvate (EP), a potent anti-inflammatory and antioxidant agent, might ameliorate delayed paralysis following thoracic aortic ischemia reperfusion (TAR). Methods C57BL6 mice were subjected to 5 minutes of thoracic aortic ischemia followed by reperfusion for up to 48 hours. Mice received either 300 mg/kg EP or lactated ringers (LR) at 30 minutes before ischemia and 3 hours after reperfusion. Neurologic function was assessed using an established rodent scale. Spinal cord tissue was analyzed for markers of inflammation (keratinocyte chemoattractant [KC], interleukin-6 [IL-6]), microglial activation (ionized calcium-binding adapter molecule-1 [Iba-1]), and apoptosis (Bcl-2, Bax, and terminal deoxynucleotidyl transferase dUTP nick end labeling [TUNEL] staining) at 24 and 48 hours after TAR. Nissl body stained motor neurons were counted in the anterior horns sections from L1-L5 segments. Results Ninety-three percent of the LR mice developed dense delayed paralysis between 40 and 48 hours after TAR, whereas only 39% of EP mice developed delayed paralysis (P <.01). Bcl-2 expression was higher (P <.05) and Iba-1 expression was lower (P <.05) in the EP group only at 24 hours reperfusion. At 48 hours, the number of motor neurons was higher (P <.01) and the number and TUNEL-positive cells was lower (P <.001) in the EP-treated mice. EP decreased the expression of KC (P <.01) and IL-6 (P <.001) at 48 hours after TAR. Conclusions The protection provided by EP against delayed paralysis correlated with preservation of motor neurons, higher expression of antiapoptotic molecules, decreased microglial cell activation, and decreased spinal cord inflammation. EP may be a treatment for humans at risk for delayed paralysis.

Original languageEnglish (US)
Pages (from-to)1433-1443
Number of pages11
JournalJournal of Vascular Surgery
Volume64
Issue number5
DOIs
StatePublished - Nov 1 2016
Externally publishedYes

Fingerprint

Paralysis
Reperfusion
Thorax
Ischemia
Motor Neurons
Chemotactic Factors
Keratinocytes
Interleukin-6
Nissl Bodies
Myelitis
Calcium
DNA Nucleotidylexotransferase
ethyl pyruvate
Horns
Transferases
Thoracic Aorta
Nervous System
Rodentia
Spinal Cord
Anti-Inflammatory Agents

ASJC Scopus subject areas

  • Surgery
  • Cardiology and Cardiovascular Medicine

Cite this

Ethyl pyruvate modulates delayed paralysis following thoracic aortic ischemia reperfusion in mice. / Nguyen, Bao Ngoc; Albadawi, Hassan; Oklu, Rahmi; Crawford, Robert S.; Fink, Mitchell P.; Cambria, Richard P.; Watkins, Michael T.

In: Journal of Vascular Surgery, Vol. 64, No. 5, 01.11.2016, p. 1433-1443.

Research output: Contribution to journalArticle

Nguyen, Bao Ngoc ; Albadawi, Hassan ; Oklu, Rahmi ; Crawford, Robert S. ; Fink, Mitchell P. ; Cambria, Richard P. ; Watkins, Michael T. / Ethyl pyruvate modulates delayed paralysis following thoracic aortic ischemia reperfusion in mice. In: Journal of Vascular Surgery. 2016 ; Vol. 64, No. 5. pp. 1433-1443.
@article{28ff5ee1bad34e979f979be0de657823,
title = "Ethyl pyruvate modulates delayed paralysis following thoracic aortic ischemia reperfusion in mice",
abstract = "Objective Delayed paralysis is an unpredictable problem for patients undergoing complex repair of the thoracic/thoracoabdominal aorta. These experiments were designed to determine whether ethyl pyruvate (EP), a potent anti-inflammatory and antioxidant agent, might ameliorate delayed paralysis following thoracic aortic ischemia reperfusion (TAR). Methods C57BL6 mice were subjected to 5 minutes of thoracic aortic ischemia followed by reperfusion for up to 48 hours. Mice received either 300 mg/kg EP or lactated ringers (LR) at 30 minutes before ischemia and 3 hours after reperfusion. Neurologic function was assessed using an established rodent scale. Spinal cord tissue was analyzed for markers of inflammation (keratinocyte chemoattractant [KC], interleukin-6 [IL-6]), microglial activation (ionized calcium-binding adapter molecule-1 [Iba-1]), and apoptosis (Bcl-2, Bax, and terminal deoxynucleotidyl transferase dUTP nick end labeling [TUNEL] staining) at 24 and 48 hours after TAR. Nissl body stained motor neurons were counted in the anterior horns sections from L1-L5 segments. Results Ninety-three percent of the LR mice developed dense delayed paralysis between 40 and 48 hours after TAR, whereas only 39{\%} of EP mice developed delayed paralysis (P <.01). Bcl-2 expression was higher (P <.05) and Iba-1 expression was lower (P <.05) in the EP group only at 24 hours reperfusion. At 48 hours, the number of motor neurons was higher (P <.01) and the number and TUNEL-positive cells was lower (P <.001) in the EP-treated mice. EP decreased the expression of KC (P <.01) and IL-6 (P <.001) at 48 hours after TAR. Conclusions The protection provided by EP against delayed paralysis correlated with preservation of motor neurons, higher expression of antiapoptotic molecules, decreased microglial cell activation, and decreased spinal cord inflammation. EP may be a treatment for humans at risk for delayed paralysis.",
author = "Nguyen, {Bao Ngoc} and Hassan Albadawi and Rahmi Oklu and Crawford, {Robert S.} and Fink, {Mitchell P.} and Cambria, {Richard P.} and Watkins, {Michael T.}",
year = "2016",
month = "11",
day = "1",
doi = "10.1016/j.jvs.2015.06.214",
language = "English (US)",
volume = "64",
pages = "1433--1443",
journal = "Journal of Vascular Surgery",
issn = "0741-5214",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - Ethyl pyruvate modulates delayed paralysis following thoracic aortic ischemia reperfusion in mice

AU - Nguyen, Bao Ngoc

AU - Albadawi, Hassan

AU - Oklu, Rahmi

AU - Crawford, Robert S.

AU - Fink, Mitchell P.

AU - Cambria, Richard P.

AU - Watkins, Michael T.

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Objective Delayed paralysis is an unpredictable problem for patients undergoing complex repair of the thoracic/thoracoabdominal aorta. These experiments were designed to determine whether ethyl pyruvate (EP), a potent anti-inflammatory and antioxidant agent, might ameliorate delayed paralysis following thoracic aortic ischemia reperfusion (TAR). Methods C57BL6 mice were subjected to 5 minutes of thoracic aortic ischemia followed by reperfusion for up to 48 hours. Mice received either 300 mg/kg EP or lactated ringers (LR) at 30 minutes before ischemia and 3 hours after reperfusion. Neurologic function was assessed using an established rodent scale. Spinal cord tissue was analyzed for markers of inflammation (keratinocyte chemoattractant [KC], interleukin-6 [IL-6]), microglial activation (ionized calcium-binding adapter molecule-1 [Iba-1]), and apoptosis (Bcl-2, Bax, and terminal deoxynucleotidyl transferase dUTP nick end labeling [TUNEL] staining) at 24 and 48 hours after TAR. Nissl body stained motor neurons were counted in the anterior horns sections from L1-L5 segments. Results Ninety-three percent of the LR mice developed dense delayed paralysis between 40 and 48 hours after TAR, whereas only 39% of EP mice developed delayed paralysis (P <.01). Bcl-2 expression was higher (P <.05) and Iba-1 expression was lower (P <.05) in the EP group only at 24 hours reperfusion. At 48 hours, the number of motor neurons was higher (P <.01) and the number and TUNEL-positive cells was lower (P <.001) in the EP-treated mice. EP decreased the expression of KC (P <.01) and IL-6 (P <.001) at 48 hours after TAR. Conclusions The protection provided by EP against delayed paralysis correlated with preservation of motor neurons, higher expression of antiapoptotic molecules, decreased microglial cell activation, and decreased spinal cord inflammation. EP may be a treatment for humans at risk for delayed paralysis.

AB - Objective Delayed paralysis is an unpredictable problem for patients undergoing complex repair of the thoracic/thoracoabdominal aorta. These experiments were designed to determine whether ethyl pyruvate (EP), a potent anti-inflammatory and antioxidant agent, might ameliorate delayed paralysis following thoracic aortic ischemia reperfusion (TAR). Methods C57BL6 mice were subjected to 5 minutes of thoracic aortic ischemia followed by reperfusion for up to 48 hours. Mice received either 300 mg/kg EP or lactated ringers (LR) at 30 minutes before ischemia and 3 hours after reperfusion. Neurologic function was assessed using an established rodent scale. Spinal cord tissue was analyzed for markers of inflammation (keratinocyte chemoattractant [KC], interleukin-6 [IL-6]), microglial activation (ionized calcium-binding adapter molecule-1 [Iba-1]), and apoptosis (Bcl-2, Bax, and terminal deoxynucleotidyl transferase dUTP nick end labeling [TUNEL] staining) at 24 and 48 hours after TAR. Nissl body stained motor neurons were counted in the anterior horns sections from L1-L5 segments. Results Ninety-three percent of the LR mice developed dense delayed paralysis between 40 and 48 hours after TAR, whereas only 39% of EP mice developed delayed paralysis (P <.01). Bcl-2 expression was higher (P <.05) and Iba-1 expression was lower (P <.05) in the EP group only at 24 hours reperfusion. At 48 hours, the number of motor neurons was higher (P <.01) and the number and TUNEL-positive cells was lower (P <.001) in the EP-treated mice. EP decreased the expression of KC (P <.01) and IL-6 (P <.001) at 48 hours after TAR. Conclusions The protection provided by EP against delayed paralysis correlated with preservation of motor neurons, higher expression of antiapoptotic molecules, decreased microglial cell activation, and decreased spinal cord inflammation. EP may be a treatment for humans at risk for delayed paralysis.

UR - http://www.scopus.com/inward/record.url?scp=84994045093&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994045093&partnerID=8YFLogxK

U2 - 10.1016/j.jvs.2015.06.214

DO - 10.1016/j.jvs.2015.06.214

M3 - Article

VL - 64

SP - 1433

EP - 1443

JO - Journal of Vascular Surgery

JF - Journal of Vascular Surgery

SN - 0741-5214

IS - 5

ER -